Mario Ramos - 02 Jan 2026 Form 4 Insider Report for Evolent Health, Inc. (EVH)

Reporting relationship: Chief Financial Officer
Issuer ticker: EVH
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2026, 16:13:26 UTC
Prior SEC filing: 01 Mar 2022
Next SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Weinberg, Attorney-in-fact

Key filing fact

Mario Ramos filed Form 4 for Evolent Health, Inc. (EVH) on 05 Jan 2026.

Key facts

This page summarizes Mario Ramos's Form 4 filing for Evolent Health, Inc. (EVH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jan 2026, 16:13.

Change

Previous filing in this sequence was filed on 01 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001891060 Primary reporting owner

Ramos Mario

Relationship: Chief Financial Officer
Address: C/O EVOLENT HEALTH, INC., 1812 N. MOORE ST., STE. 1705, ARLINGTON
Signature: /s/ Jonathan Weinberg, Attorney-in-fact
Signature date: 05 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVH transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +587,500
Change %
Price: $0.000000
Shares after: 587,500
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a special one-time restricted stock unit grant to Mr. Ramos, pursuant to an employment inducement award under Rule 303A.08 of the New York Stock Exchange Listing Manual. Upon vesting, each unit is converted into one share of Class A Common Stock, contingent on Mr. Ramos's continued employment through the applicable vesting date.

Footnote F2

Securities vest at a rate of 34% on January 2, 2027, and 33% on January 2, 2028, and January 2, 2029.